Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma.
Cutaneous T-cell lymphoma (CTCL) is typically a skin-infiltrating, clonal proliferative disorder of CD4+ T cells that exhibit a T-helper type 2 cytokine phenotype. Therapeutic decisions are based on the extent of disease and the observations that host-antitumor responses occur and that these responses may be blunted by the immunosuppressive cytokines produced by the malignant T cells. Biologic response modifiers, which may enhance cell-mediated immunity and antitumor responses, are active agents in the treatment of CTCL. The rationale and use of biologic response modifiers to treat CTCL are reviewed in this article.
Rook
A H
AH
Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.
Yoo
E K
EK
Grossman
D J
DJ
Kao
D M
DM
Fox
F E
FE
Niu
Z
Z
D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016410:Lymphoma, T-Cell, Cutaneous / Q000628:therapy*
D007155:Immunologic Factors